Apogee Therapeutics Inc Quick Ratio (APGE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
APGE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 25.91 above Apogee Therapeutics Inc average.
Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Quick Ratio than Apogee Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 75 to 170.
Revolutionizing Inflammation and Immunology: Insights from Apogee Therapeutics’ Upcoming Virtual RandD Day In an era where innovation in drug development remains pivotal, Apogee Therapeutics is poised to make significant strides in the field of Inflammation and Immunology (IandI). As the company prepares for its inaugural virtual RandD day on December 2, 2024, it aims to highlight critical advancements in its therapeutic pipeline. This event is particularly significant as Apogee claims to be on a path to reshape the standard of care in IandI, with an emphasis on developing best-in-class monotherapy and combination treatments. Pipeline Progress: A Closer Look During the upcoming RandD Day, Apogee Therapeutics will showcase its current progress across its therapeutic pipeline. Though specific drug candidates and their phases of development have yet to be publicly detailed, the company has signaled a commitment to advancing specialized treatments. Their focus on both monotherapy and combination therapy places them in a favorable position to meet diverse patient needs, especially for those affected by complex inflammatory disorders.
Apogee Therapeutics, Inc. Seeks Funding for Biologics Development Through Public Offering SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 Apogee Therapeutics, Inc. (Nasdaq: APGE), a leading clinical-stage biotechnology company specializing in the development of biologics for inflammatory and immunology indications, has announced the commencement of an underwritten public offering of approximately $350.0 million of shares of its common stock. The company also plans to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock. Apogee Therapeutics Inc. s recent financial performance indicates positive growth, with a significant increase in cash and cash equivalents by 238.1% in the third quarter of 2023. This growth has contributed to an improved Quick Ratio of 24.62, although it still ranks lower compared to some competitors in the industry. Over the past twelve months, the company s Quick Ratio has more than doubled, reaching 15.75, but remains below the company s 12-month average.
On the trailing twelve months basis APGE Cash & cash equivalent soared by 92.3 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Apogee Therapeutics Inc 's Quick Ratio to 24.84, above APGE average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Apogee Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2143 to 3495.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
